Barrett Katz - 09 Jan 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Medical Officer
Signature
/s/ Lara Meisner, Attorney-in-Fact for Barrett Katz
Issuer symbol
VRDN
Transactions as of
09 Jan 2023
Net transactions value
-$707,672
Form type
4
Filing time
11 Jan 2023, 18:09:33 UTC
Previous filing
03 Feb 2022
Next filing
18 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $290,708 +12,623 $23.03 12,623 09 Jan 2023 Direct
transaction VRDN Common Stock Sale $417,064 -12,623 -100% $33.04 0 09 Jan 2023 Direct F1
transaction VRDN Common Stock Options Exercise $1,091,092 +47,377 $23.03 47,377 10 Jan 2023 Direct
transaction VRDN Common Stock Sale $1,672,408 -47,377 -100% $35.30 0 10 Jan 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -12,623 -3.5% $0.000000 343,377 09 Jan 2023 Common Stock 12,623 $23.03 Direct F3
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -47,377 -14% $0.000000 296,000 10 Jan 2023 Common Stock 47,377 $23.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $33.00 to $33.135. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $33.76 to $35.934. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.